153 related articles for article (PubMed ID: 37163360)
21. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Peripheral T-Cell Lymphoma in Community Settings.
Feldman T; Farber CM; Choi K; Faria C; Goy A; Connors J; Paramanathan D; Kaur S; Schultz E; McGuire M; Goldberg SL
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):354-361. PubMed ID: 28622960
[TBL] [Abstract][Full Text] [Related]
23. Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India.
Nemani S; Korula A; Agrawal B; Kavitha ML; Manipadam MT; Sigamani E; George B; Srivastava A; Viswabandya A; Mathews V
Indian J Med Res; 2018 May; 147(5):464-470. PubMed ID: 30082570
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
[No Abstract] [Full Text] [Related]
25. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia.
Yoon SE; Song Y; Kim SJ; Yoon DH; Chen TY; Koh Y; Kang KW; Lee HS; Tay KKW; Lim ST; Poon M; Irawan C; Zhao W; Do YR; Lee MH; Ng SC; Lee WS; Guo Y; Zhang H; Kang HJ; Yun HJ; Kim HJ; Lung DTC; Kwak JY; Han JJ; Mun YC; Oh SY; Shim H; Kwon JH; Sohn BS; Park SK; Jo JC; Ko YH; Jun Z; Kim WS
Lancet Reg Health West Pac; 2021 May; 10():100126. PubMed ID: 34327343
[TBL] [Abstract][Full Text] [Related]
26. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group.
Torimoto Y; Sato K; Ikuta K; Hayashi T; Hirayama Y; Inamura J; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Mori A; Ota S; Sakai H; Shigematsu A; Shindo M; Shinzaki H; Takahashi F; Takimoto R; Tanaka J; Yamamoto S; Kohgo Y; Fukuhara T
Int J Hematol; 2013 Aug; 98(2):171-8. PubMed ID: 23813410
[TBL] [Abstract][Full Text] [Related]
27. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
28. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
[TBL] [Abstract][Full Text] [Related]
29. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Ludvigsen Al-Mashhadi A; Cederleuf H; Kuhr Jensen R; Holm Nielsen T; Bjerregård Pedersen M; Bech Mortensen T; Relander T; Jerkeman M; Ortved Gang A; Kristensen AL; Roost Clausen M; de Nully Brown P; Tang Severinsen M; Jakobsen LH; Ellin F; El-Galaly TC
Am J Hematol; 2023 Mar; 98(3):388-397. PubMed ID: 36588403
[TBL] [Abstract][Full Text] [Related]
30. [Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation].
Zou D; Huang W; Liu H; Fu M; Li Z; Sui W; Qi J; Zhao Y; Ru K; Han M; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):455-9. PubMed ID: 26134007
[TBL] [Abstract][Full Text] [Related]
31. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
32. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
[TBL] [Abstract][Full Text] [Related]
33. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
34. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
Ellin F; Landström J; Jerkeman M; Relander T
Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
36. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
37. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.
Yamasaki S; Yoshida S; Kato K; Choi I; Imamura Y; Kohno K; Henzan H; Tanimoto K; Ogawa R; Suehiro Y; Miyamoto T; Eto T; Ohshima K; Akashi K; Iwasaki H;
Int J Hematol; 2020 Jul; 112(1):74-83. PubMed ID: 32297159
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.
Kim HD; Cho H; Sohn BS; Park CS; Huh J; Ryu JS; Lee SW; Yoon SE; Kim SJ; Ko YH; Kim WS; Suh C
Leuk Lymphoma; 2022 Jan; 63(1):124-130. PubMed ID: 34702115
[TBL] [Abstract][Full Text] [Related]
39. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
40. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
Shustov A; Cabrera ME; Civallero M; Bellei M; Ko YH; Manni M; Skrypets T; Horwitz SM; De Souza CA; Radford JA; Bobillo S; Prates MV; Ferreri AJM; Chiattone C; Spina M; Vose JM; Chiappella A; Laszlo D; Marino D; Stelitano C; Federico M
Blood Adv; 2021 Feb; 5(3):640-648. PubMed ID: 33560375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
